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Completion of early stages of retrovirus infection depends on the cell cycle. While gammaretroviruses require mitosis
for proviral integration, lentiviruses are able to replicate in post-mitotic non-dividing cells. Resting cells such as naive
resting T lymphocytes from peripheral blood cannot be productively infected by retroviruses, including lentiviruses,
but the molecular basis of this restriction remains poorly understood. We demonstrate that in G0 resting cells (primary
fibroblasts or peripheral T cells), incoming foamy retroviruses accumulate in close proximity to the centrosome, where
they lie as structured and assembled capsids for several weeks. Under these settings, virus uncoating is impaired, but
upon cell stimulation, Gag proteolysis and capsid disassembly occur, which allows viral infection to proceed. The data
imply that foamy virus uncoating is the rate-limiting step for productive infection of primary G0 cells. Incoming foamy
retroviruses can stably persist at the centrosome, awaiting cell stimulation to initiate capsid cleavage, nuclear import,
and viral gene expression.
Citation: Lehmann-Che J, Renault N, Giron ML, Roingeard P, Clave E, et al. (2007) Centrosomal latency of incoming foamy viruses in resting cells. PLoS Pathog 3(5): e74. doi:10.
1371/journal.ppat.0030074
Introduction
After entry into their host cells, retroviruses undergo
uncoating and reverse transcription, leading to the formation
of pre-integration complexes, which must then gain access to
the nuclear compartment and integrate the provirus into
host chromosomes [1]. The cell cycle status is a key
determinant for completion of these early stages of infection
[2], and retroviruses have been classiﬁed based on their ability
to productively infect non-cycling cells. Gammaretroviruses,
like murine leukemia virus, require mitosis for proviral
integration [3], while lentiviruses such as human immunode-
ﬁciency virus type 1 (HIV-1) show almost no difference
between dividing and non-dividing cells [4]. Indeed, HIV-1
and other lentiviruses can replicate in terminally differ-
entiated and post-mitotic cells such as neurons or macro-
phages [5,6]. However, like murine leukemia virus, HIV-1
cannot infect naive quiescent CD4-positive T cells or
monocytes isolated from peripheral blood that are in the
G0 stage of the cell cycle [2,7]. Since reverse transcription
does occur in these conditions [8], it is conceivable that other
host cell proteins or processes are necessary for the
completion of the viral cycle [9].
Foamy viruses (FVs) are complex retroviruses isolated from
different animal species, mainly in non-human primates. FVs
share with all retroviruses the same organization of the
genome, which encodes Gag, Pol, and Env proteins. In
addition, the FV genome encodes at least two other proteins,
Tas and Bet, which are not incorporated into the viral
particle. Remarkably, FVs exhibit some features related to the
hepatitis B virus [10]. In particular, they reverse transcribe
their RNA genome during the late stages of infection, leading
to the presence of infectious viral DNA in extracellular
virions [11]. Moreover, the structural FV Gag presents speciﬁc
characteristics that set it clearly apart from other retroviral
Gag proteins. In particular, FV Gag maturation by the viral
protease does not lead to the formation of the canonical
matrix, capsid, and nucleocapsid products. Rather, the Gag
precursor is partially cleaved by the viral protease near its C
terminus into a mature product, before or during budding.
This results in the presence of two Gag proteins of 71 kDa
and 68 kDa in extracellular virions [12]. We have previously
reported that upon entry into target cells and prior to
nuclear translocation, incoming FV capsids trafﬁc along the
microtubule network to reach the microtubule-organizing
centre (MTOC) [13,14], which includes the centrosome in
animal cells [15]. A similar route has been described for HIV-
1 [16]. Drugs disrupting the microtubule network, such as
nocodazole or colchicine, largely prevent early intracellular
FV trafﬁcking [13], as well as that of HIV-1 [16]. Gag also
targets the pericentrosomal region for capsid assembly
during the late stages of infection [17]. Similar to murine
leukemia virus, productive FV infection requires passage
through mitosis [18,19]. Like all other animal retroviruses,
FVs do not productively infect cells arrested in the G0 stage
of the cell cycle, such as peripheral T lymphocytes or growth-
arrested ﬁbroblasts in vitro [19]. To gain insight into this
Editor: John A. T. Young, Salk Institute for Biological Studies, United States of
America
Received October 17, 2006; Accepted April 6, 2007; Published May 25, 2007
Copyright:  2007 Lehmann-Che et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Abbreviations: ab, antibody; CHX, cycloheximide; EM, electron microscopy; FV,
foamy virus; HIV-1, human immunodeficiency virus type 1; m.o.i., multiplicity of
infection; MTOC, microtubule-organizing centre; p.i., post-infection; PFV, primate
foamy virus
* To whom correspondence should be addressed. E-mail: ali.saib@
univ-paris-diderot.fr
[ These authors contributed equally to this work.
PLoS Pathogens | www.plospathogens.org May 2007 | Volume 3 | Issue 5 | e74 0683restriction, we have focused our attention on early stages of
FV replication in G0 cells.
Here, we demonstrate that incoming FVs stably localize at
the vicinity of the MTOC as structured and assembled capsids
for several weeks in resting cultures in vitro. Upon cell
stimulation, Gag proteolysis and capsid disassembly take
place, allowing infection to proceed. Altogether, these data
demonstrate that the centrosome represents a cellular site
around which incoming viruses persist as a stable pre-
integration intermediate in resting cells, and that virus
uncoating is the rate-limiting step for FV infection in
growth-arrested cells.
Results
Cycling and resting human primary MRC5 ﬁbroblastic cells
were infected with the prototypic primate foamy virus (PFV)
at a multiplicity of infection (m.o.i.) of 1, and cell-free
supernatant was collected 48 h later for virus titration.
Consistent with previous reports [18,19], we found that PFV
does not productively infect G0 resting cells (unpublished
data). To investigate the molecular mechanisms involved in
the restriction of FV replication cycle in G0 resting cells, we
ﬁrst analyzed the distribution of incoming viral components
in resting MRC5 cells. As early as 4 h post-infection (p.i.)., we
observed that incoming Gag proteins localized at the
centrosome, which was revealed with anti-c-tubulin anti-
bodies (abs). These ﬁndings are consistent with previous
observations showing the pericentrosomal concentration of
incoming FVs after trafﬁcking along the microtubule network
in cycling cells [13]. Remarkably, while in cycling cells,
incoming Gag antigens are no longer observed near this
organelle 10 h p.i. ([20]; unpublished data); in resting cells,
centrosomal localization of viral antigens was consistently
observed up to 30 d p.i. (Figure 1A). We then investigated the
localization of the viral genome in infected resting cells. By
ﬂuorescent in situ hybridization, using the entire PFV DNA
genome as a probe, we found that the incoming viral DNA
genome also localized at the centrosome in resting MRC5
cells 15 d p.i. (Figure 1B). Therefore, both incoming FV
antigens and the viral DNA genome reside at the MTOC of
resting cells for several weeks after infection.
To visualize the status (assembled capsids or not) of
incoming viruses in resting cells, MRC5 cells were analyzed
by electron microscopy (EM) at different time points after
infection. In cycling cells (Figure 2A), incoming FVs were
observed at the centrosome 4 h p.i., mainly as structured and
assembled capsids, conﬁrming that uncoating is not complete
at this time point [20]. At later time points, these viral capsids
completely disassembled in cycling cells as already reported
[20], and viral capsids were never detected in uninfected cells
(Figure 2A). Importantly, assembled and structured viral
capsids were observed around the centrosome in resting cells
5 or 15 d p.i. (Figure 2A), strongly suggesting that virus
uncoating is impaired under these settings.
FV uncoating requires the enzymatic activity of both viral
and cellular proteases, which cleave the major structural
components of viral capsids (the 71–68 kDa Gag doublet),
into shorter fragments [20]. Among these cleavage products, a
38-kDa Gag-derived product speciﬁcally results from the
action of the viral protease [20]. To conﬁrm at the
biochemical level that FV uncoating is inhibited in resting
cells, the status of the Gag polyprotein was determined. For
that purpose, resting and cycling MRC5 cells were infected
with PFV at an m.o.i. of 1, and intracellular viral proteins
were analyzed by Western blot using mouse anti-Gag abs.
Figure 2B shows that Gag cleavage products, in particular the
38-kDa fragment, were easily detected in cycling cells. On the
contrary, FV Gag was not cleaved following infection of
resting MRC5 cells and remained as an intact doublet of 71
and 68 kDa (Figure 2B). These results demonstrate the
absence of Gag cleavage in resting cells, reﬂecting the
absence of viral uncoating observed by EM.
To assess whether incoming FV capsids at the centrosome
of resting cells constitute a stable pre-integration intermedi-
ate, which can later be reactivated for productive infection,
resting PFV-infected MRC5 cell cultures were stimulated to
divide by splitting and serum addition. At different time
points following this activation, Gag expression and distri-
bution were analyzed by indirect immunoﬂuorescence using
mouse anti-Gag abs. Twenty-four hours after cell activation,
we observed that, although Gag still associated to the
centrosome, it could be detected in both the cytoplasm and
the nucleus of 20% of the cells (Figure 3A). Gag was detected
in both compartments in the entire culture 48 h after cell
activation, and the formation of numerous syncytia was
detected 96 h post-activation (Figure 3A). These results
demonstrate that viral replication, which was inhibited in
resting cells, resumes upon cell activation. To conﬁrm that
cell activation actually triggered virus uncoating, the status of
the Gag polyprotein was studied by Western blot. To
exclusively analyze incoming viral antigens, avoiding con-
tamination from Gag synthesis and degradation, which might
occur following reactivation, these experiments were per-
formed under cycloheximide (CHX) treatment, a translation
inhibitor. At 24 h post-reactivation, several Gag cleavage
products, notably the 38-kDa fragment [20], were clearly
detected in CHX-treated cells (Figure 3B). Moreover, under
these settings, accumulation of Gag was observed only in
untreated reactivated cells. Altogether, these observations
demonstrated that entry into the cell cycle triggered virus
uncoating, as assessed by Gag cleavage, and productive
infection.
Several reports have demonstrated that FVs infect lym-
phocytes in vivo and that infectious particles can be
recovered from peripheral T cells of infected animals
[21 24]. Therefore, the intracellular distribution of incoming
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Author Summary
Naive quiescent CD4-positive T cells or monocytes that are in the G0
stage of the cell cycle cannot be productively infected by
retroviruses in vitro, but the molecular basis of this restriction
remains poorly understood. In this report, we demonstrate that
incoming foamy retroviruses remain around the centrosome as
structured and assembled capsids for weeks in resting cultures.
Under these conditions, virus uncoating is impaired, but upon cell
activation, viral capsids undergo proteolysis and disassembly,
allowing infection to proceed. Maintenance of incoming viral
capsids at the centrosome in resting cells could be a strategy that
viruses have evolved to rapidly respond to stimuli received by the
cell. The cellular signal triggering the uncoating process upon cell
stimulation remains unclear, but is likely linked to the centrosome
cycle.FVs was assessed in one of its natural targets. To this aim,
primary resting human CD4-positive T cells were infected
with PFV at an m.o.i of 1 and were maintained in a resting
state in culture for 5 d without addition of exogenous
lymphokines. PFV infection of resting CD4-positive T cells
was non-productive (unpublished data) and did not trigger
cell activation (Figure 4A). In these cells, localization of
incoming capsids was analyzed by confocal microscopy.
Consistent with our previous observation of infected resting
MRC5 cells, incoming Gag strictly localized at the centrosome
from day 2 to day 5 p.i. (Figure 4B). On the contrary, Gag was
diffusely distributed in the cytoplasm and the nucleus of
activated CD4-positive T cells, indicating that productive
replication was taking place in these cells (Figure 4B) [25].
When resting CD4-positive T cells were stimulated to divide 5
d p.i., Gag was no longer observed uniquely at the
centrosome but localized diffusely in the cytoplasm and the
nucleus at 24 h post-activation (Figure 4B). Taken together,
these results conﬁrm that a stable PFV intermediate can
persist in the vicinity of the MTOC in primary resting CD4-
positive T cells and that T cell activation allows completion
of the viral replication cycle.
Discussion
For all retroviruses, completion of the early steps of the
replication cycle depends on the cell cycle status (reviewed in
[2,9]). We show that in vitro FV infection is restricted in G0
resting cells, either from ﬁbroblastic (MRC5) or lymphocytic
(CD4-positive T cells) origin. We further demonstrate that
incoming viral capsids persist in infected G0 resting cells as a
stable pre-integration intermediate over a period of at least
30 d in MRC5 cells. Under these conditions, Gag proteolysis,
and consequently virus uncoating, is blocked, and incoming
viruses are maintained as assembled and structured capsids
Figure 1. Intracellular Localization of Incoming PFV in Resting MRC5 Cells
(A) Sub-cellular localization of incoming Gag proteins studied by confocal microscopy following indirect immunofluorescence at 3, 15, and 30 d p.i.
using anti-Gag antiserum (green). At these time points, Gag is exclusively detected at the MTOC, stained with c-tubulin abs (red). Nuclei are stained with
DAPI (blue).
(B) Sub-cellular localization of the viral DNA genome from incoming PFV analyzed by confocal microscopy following in situ hybridization 15 d p.i. using
a biotin-labeled PFV full-length probe (green). As well as incoming Gag, the viral DNA genome localizes at the MTOC (revealed with anti-c-tubulin abs,
red) 15 d p.i. Nuclei are stained with DAPI (blue).
doi:10.1371/journal.ppat.0030074.g001
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viral capsids disassemble, and infection proceeds.
Post-mitotic cells such as neurons or macrophages are
productively infected by lentiviruses. In contrast, resting G0
cultures in vitro, such as naive T lymphocytes isolated from
peripheral blood, cannot be productively infected by any
classes of retroviruses, including HIV-1 [8,26 30]. Since
reverse transcription is completed in these cells [8,28],
additional blocks seem to occur during the early stages of
the virus life cycle. Several hypotheses have been raised to
elucidate the molecular basis of this restriction. It has been
suggested that APOBEC3G, a cellular antiretroviral protein
that is associated with the hypermutation of viral DNA
through cytidine deamination [31], could inhibit HIV
Figure 2. Characterization of Incoming PFV Particles in Resting MRC5
Cells
(A) Electron micrographs of uninfected and infected cycling and resting
cells. Normally shaped intracellular capsids (pointed out by a black arrow)
are observed in PFV-infected cycling cells at 4 h p.i. In resting cells at 5 or
15 d p.i., similar intact capsids (pointed out by a black arrow) are
observed surrounding the MTOC. High magnifications are presented in
the right corner. No viral capsids are detected in uninfected cells.
(B) Western blot analysis of protein extracts from PFV-infected cycling
and resting cells using anti-Gag abs. Analysis of protein lysates performed
7 h p.i. in cycling cells reveals the presence of the characteristic Gag
doublet (71–68 kDa) and early Gag cleavage products. The 38-kDa Gag
product (*) results from the action of the viral protease. In resting cells, 5
or 15 d p.i., these shorter Gag products are absent.
doi:10.1371/journal.ppat.0030074.g002
Figure 3. Reactivation of PFV-Infected Resting Cells
(A) Sub-cellular localization of Gag proteins (green) studied by confocal
microscopy following indirect immunofluorescence using anti-Gag
antiserum. Thirty days p.i., Gag proteins mainly localize at the MTOC
(stained with anti-c-tubulin abs in red) in resting cells. In contrast, Gag
proteins are detected both in the cytoplasm and the nucleus of these
cells at 24, 48, and 96 h post-activation by splitting and serum addition.
Syncitia, characteristic of a productive FV infection, appear 96 h post-
reactivation.
(B) Western blot analysis of protein extracts from resting and activated
PFV-infected cells with or without CHX treatment (150 lg/ml). At 30 d p.i.
(with m.o.i. of 2), only the Gag doublet at 68 and 71 kDa is detected in
resting cells using anti-Gag abs. Under CHX treatment, at 24 h post-
reactivation, Gag cleavages are clearly detected, including the 38-kDa
Gag product (*) involved in virus uncoating [20].
doi:10.1371/journal.ppat.0030074.g003
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complex in resting T cells. This seems to impair the
formation of HIV-1 late reverse transcription products [29].
A recent alternative hypothesis suggests that virus uncoating
represents the main rate limiting stage in resting T CD4þ
cells, since cellular extracts from activated, but not resting
cells, support uncoating of HIV cores in vitro [30,32]. Clearly,
our observations suggest this second scenario in the case of
FVs. Interestingly, our observations might explain the
efﬁcient in vivo transduction of haematopoietic stem cells
by FV-derived vectors in mice [33,34]. Indeed, despite the fact
that FVs cannot productively infect resting stem cells in vitro,
FV vectors can repopulate bone marrow [33 36]. In fact, in
vivo implantation of transduced resting stem cells likely
triggers their activation, allowing the infection to proceed.
The remarkable stability of the FV intermediate in resting
cells that we have evidenced here could be related to the
particular mode of replication of these viruses. First, virus
uncoating is a relatively late event during FV replication,
allowing incoming viral antigens to accumulate in close
vicinity to the nuclear compartment as assembled and
structured capsids [13,20]. On the contrary, for HIV-1, capsid
disassembly in activated and cycling cells seems to start as
soon as the viral particles enter into the cytoplasm [16,37].
Figure 4. Intracellular Localization of Incoming PFV in Quiescent and Activated CD4-positive T Cells
(A) Flow cytometry profile of isolated human resting CD4-positive T cells. Purity of sorted cells is at least 99% and no cell activation is observed 5 d p.i.
(B) Sub-cellular localization of Gag proteins studied by confocal microscopy following indirect immunofluorescence using anti-Gag antiserum (green). In
activated CD4-positive T cells at 48 h p.i., Gag proteins are not restricted to the MTOC but diffusely localize in the cytoplasm and in the nucleus (top
row). In resting CD4-positive T cells at 2 and 5 d p.i., Gag proteins co-localize with c-tubulin (red), the MTOC marker. Twenty-four hours following cell
stimulation of 5 d infected resting CD4-positive T cells, Gag proteins diffusely localize in the cytoplasm and in the nucleus, similar to what we observed
in activated CD4-positive T cells (bottom row).
doi:10.1371/journal.ppat.0030074.g004
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infectious viral DNA genome in incoming capsids could make
FV less dependent on the metabolism of the target cell [11].
Our data also demonstrate that the centrosome is a cellular
site around which incoming FVs can stably persist, awaiting
further cell stimulation for completion of the viral cycle.
Recent studies have shown that the centrosome is not a mere
spectator of the cell cycle but can exert signiﬁcant control
over it [38]. By providing a scaffold for many cell cycle
regulators and their activities [38 40], the centrosome
inﬂuences cell cycle progression, especially during the
transition from G1 to S phase [41,42]. Therefore, this
organelle receives and integrates signals from outside the
cell and facilitates conversion of these signals into cellular
functions. Maintenance of viral capsids at the vicinity of the
centrosome in resting cells could be a strategy that some
viruses have evolved to rapidly respond to growth stimuli
received by the cell. The cellular signal(s) triggering the
uncoating process upon cell stimulation remains unclear, but
is likely linked to the centrosome cycle.
Materials and Methods
Cell cultures. Human MRC5 ﬁbroblasts were cultured as described
[14]. Quiescent MRC5 ﬁbroblasts were generated following conﬂu-
ence, serum starvation, and addition of 10
 6 M dexamethasone. The
cells were cultured in these conditions for 10 d before infection. The
cell cycle status was analyzed by pyronine staining as described by
[43]. In resting MRC5 cells, less than 3% of cells remain activated, as
already reported ([44]; unpublished data). For cell activation, cells
were stimulated to divide by subculture and serum addition at
different times after infection. CHX treatment was performed at 150
lg/ml immediately after cell activation and maintained during the
entire experiment.
Peripheral blood mononuclear cells obtained from healthy donors
after informed consent were separated on lymphocytes separation
medium (Eurobio, http://www.eurobio.fr). CD4-positive T cells were
negatively selected using the CD4-positive T Cell Isolation Kit II
(Miltenyi Biotec, http://www.miltenyibiotec.com). Brieﬂy, cells were
labeled using a cocktail of biotin-conjugated abs against CD8, CD16,
CD19, CD36, CD56, CD123, TCRcd, and glycophorin A, and anti-
biotin magnetic beads. After washing, negative cells were selected by
magnetic separation with the autoMACS Separator (Miltenyi Biotec).
The cells were then labeled with FITC-anti-CD8 (clone SK1; BD
Biosciences, http://www.bdbiosciences.com), anti-CD14 (Clone TUK4,
Miltenyi Biotec), Phycoerythrin-conjugated anti-CD25 (clone 4E3,
Miltenyi Biotec), and anti HLA-DR (L243, BD Biosciences) ab, washed,
and sorted on a FACSVantage. The purity was examined by ﬂow
cytometry with the same ab and an allophycocyanin-conjugated anti-
CD4 (clone RPA-T4, BD Biosciences). Typically, cells were more than
99% negative for the activation markers (CD25 and HLA-DR) and
more than 98% positive for the CD4. Activated CD4-positive T cells
were prepared by incubating negatively selected CD4 T cells in RPMI
10% normal human serum and 1 lg/ml PHA-L (Sigma, http://www.
sigmaaldrich.com). At day 3, 150 UI/ml of interleukin 2 (IL-2;
Promocell, http://www.promocell.com) was added to the cells.
Activation status of the control and infected CD4 T cells were
checked by ﬂow cytometry with the ab anti-CD4 FITC and an anti-
CD25 or HLA DR PE ab.
PFV infection and titration. MRC5 cultures or CD4-positive T cells
were infected by spinoculation at an m.o.i. of 1 for 1 h 30 min at 30
8C. Titres were determined by infection using FAG cells (BHK cells
stably harbouring the GFP gene under the control of the PFVU3
promoter) [45].
Immunocytochemistry. MRC5 cells grown on glass coverslips were
infected with PFV at an m.o.i. of 1 by spinoculation for 1 h 30 min at
30 8C. After different times p.i., cells were rinsed with PBS, ﬁxed for
10 min at 4 8C with 4% PFA, and permeabilized for 5 min at  20 8C
with ice-cold methanol. Cells were incubated successively with mouse
polyclonal anti-Gag serum overnight at 4 8C (1/250) and with rabbit
polyclonal c-tubulin antiserum (1/2000; Abcam, http://www.abcam.
com) for 1 h at 37 8C. Cells were washed and incubated for 1 h with a
1/500 dilution of appropriate ﬂuorescent-labeled secondary abs.
Nuclei were stained with 4’-6-diamidino-2-phenylindole (DAPI) and
the coverslips were mounted in Moviol. Confocal microscopy
observations were performed with a laser-scanning confocal micro-
scope (LSM510 Meta; Carl Zeiss, http://www.zeiss.com) equipped with
an Axiovert 200 M inverted microscope using a Plan Apo 63_/1.4-N
oil immersion objective.
Immunolocalization in combination with ﬂuorescence in situ
hybridization. Fifteen days following PFV infection (m.o.i. of 1),
arrested MRC5 cells were ﬁxed with 4% PFA, permeabilized with
0.2% Triton X-100, and incubated with c-tubulin antiserum (Abcam).
Then, cells were ﬁxed a second time in 4% PFA for 20 min at room
temperature to cross-link bound abs. Incubation with the secondary
ab was performed during the ﬂuorescent in situ hybridization
detection step, performed as described [20]. Brieﬂy, cells were treated
with RNase at 100 lg/ml in PBS for 30 min at 37 8C and incubated
with probe (plasmid p13 containing the entire PFV genome)
overnight at 37 8C. Probes were labeled with FITC-avidin DN (1/
200; Vector Laboratories, http://www.vectorlabs.com) and signals were
ampliﬁed with biotinylated anti-avidin D (1/500, Vector Laborato-
ries), followed by another round of FITC-avidin staining. Finally, cells
were stained for DNA with DAPI and mounted in Vectashield.
Confocal observations were performed as previously described.
Western blot analysis. Cell pellets were lysed in Triton buffer (10
mM Tris [pH 7.4]; 50 mM NaCl; 3 mM MgCl2; 1 mM CaCl2;
orthovanadate, benzamidine, and protease inhibitor cocktail [Roche,
http://www.roche.com] at 1 mM each; 10 mM NaF; and 0.5% Triton X-
100) for 30 min at 4 8C and centrifuged for 15 min at 20,000g.
Resulting pellets were treated with radioimmunoprecipitation buffer
(10 mM Tris [pH 7.4]; 150 mM NaCl; orthovanadate, benzamidine,
and protease inhibitor cocktail at 1 mM each; 10 mM NaF; 1%
deoxycholate; 1% Triton X-100; and 0.1% sodium dodecyl sulfate
[SDS]) during an additional 30 min at 4 8C, centrifuged for 15 min at
20,000g, collected, and diluted in Laemmli buffer. Samples were
migrated on an SDS–10% polyacrylamide gel, and proteins were
transferred onto cellulose nitrate membrane (Optitran BA-S83;
Schleicher-Schuell, http://www.schleicher-schuell.com), incubated
with appropriated abs, and detected by enhanced chemiluminescence
(Amersham ECL Advance Western Blotting Detection Kit, http://www.
gelifesciences.com).
Electron microscopy. For EM studies, MRC5 cells were infected at
an m.o.i. of 5 as described above and ﬁxed in situ by incubation for 48
h in 4% PFA and 1% glutaraldehyde in 0.1 M phosphate buffer (pH
7.2); they were then post-ﬁxed by incubation for 1 h with 2% osmium
tetroxide (Electron Microscopy Science, http://www.emsdiasum.com).
Next, MRC5 cells were dehydrated in a graded ethanol series, cleared
in propylene oxyde, and then embedded in Epon resin (Sigma), which
was allowed to polymerize for 48 h at 60 8C. Ultrathin sections were
cut, stained with 5% uranyl acetate/5% lead citrate, and then placed
on EM grids coated with collodion membrane. They were then
observed with a Jeol 1010 transmission electron microscope (Jeol,
http://www.jeol.com).
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